latest update:
[TrialBase DB]

trial summary · NCT07135882

Primary Radiotherapy In MEtastatic Lung Cancer

A Randomised Phase III Trial of Up-front Radiotherapy With Standard-of-care Systemic Therapy in Advanced Lung Cancer

Trial record from the TrialBase DB dataset, status RECRUITING, condition Carcinoma, Non-Small-Cell Lung (NSCLC), sponsored by Trans Tasman Radiation Oncology Group. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07135882phase PHASE3enrollment 420start 2026-10-30

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Lung cancer has the highest mortality rate of all cancers in Australia and is an area of unmet need. It starts in the lung (the primary tumour), and then spreads (metastasise) to other organs. The PRIME-Lung clinical trial will investigate if radiotherapy to the primary lung tumour, in addition to standard drug therapies, for patients with metastatic lung cancer will lead to less spread of cancer, prolong life, improve patient well-being and be cost-effective for the health care system.

Source record: https://clinicaltrials.gov/study/NCT07135882

Facts

registry idNCT07135882
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE3
study typeINTERVENTIONAL
lead conditionCarcinoma, Non-Small-Cell Lung (NSCLC)
sponsorTrans Tasman Radiation Oncology Group
sponsor classOTHER
enrollment420
start date2026-10-30
primary completion2030-12-31
completion2036-12-31
results postednot reported

Conditions

  • Carcinoma, Non-Small-Cell Lung (NSCLC)

Interventions

  • Radiotherapy followed by chemotherapy
  • Standard of Care (SOC)

Countries

  • Australia

Intervention types: COMBINATION_PRODUCT, DRUG

Work with this record